The Foundation for the National Institutes of Health's Biomarkers Consortium has shared the data of a proteomics study performed utilizing plasma samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with scientists globally for further analysis.
The study represented the work of the Biomarkers Consortium project: Use of Targeted Multiplex Proteomic Strategies to identify plasma-based biomarkers in Alzheimer's disease. The project team comprised of representatives from academia, industry and government developed and executed this project and also developed a statistical analysis plan.
The project was intended to be the first part of a multi-phased effort seeking to utilize samples collected by ADNI to qualify multiplex panels in both plasma and cerebrospinal fluid to diagnose patients with Alzheimer's disease and monitor disease progression.
ADNI involves longitudinal MRI and PET brain imaging and blood, urine and spinal fluid biomarker studies of more than 800 individuals, half of whom have mild cognitive impairment. A renewal of the ADNI effort was announced in October by the Foundation for NIH and National Institute on Aging, which will continue ADNI for an additional five years through late 2015.